Table 2.

The prescription prevalence of 11 classes of psychotropic medications from 2013 to 2017 in urban China.

	Prevalence of use, % (95% CI)
Drug	2013	2014	2015	2016	2017	Relative increase (%) a	P b
Sedatives-hypnotics	3.177 (3.174–3.179)	3.018 (3.016–3.021)	3.292 (3.289–3.294)	4.281 (4.278–4.284)	5.388 (5.385–5.391)	69.61	0.007
Anxiolytics	1.436 (1.435–1.438)	1.315 (1.314–1.317)	1.505 (1.503–1.507)	1.943 (1.941–1.945)	2.200 (2.198–2.202)	53.17	0.036
Antiepileptic drugs	1.416 (1.414–1.417)	1.284 (1.283–1.286)	1.497 (1.496–1.499)	1.836 (1.834–1.837)	2.140 (2.138–2.142)	51.15	0.001
Nootropic drugs	2.378 (2.376–2.380)	2.233 (2.231–2.235)	2.759 (2.757–2.762)	1.645 (1.643–1.646)	2.009 (2.007–2.011)	−15.51	0.49
Antipsychotics	0.809 (0.807–0.810)	0.745 (0.743–0.746)	0.763 (0.762–0.765)	0.987 (0.985–0.988)	1.156 (1.155–1.158)	42.99	0.001
Antidepressants	0.891 (0.890–0.893)	0.742 (0.741–0.743)	0.716 (0.715–0.718)	0.922 (0.921–0.924)	1.045 (1.044–1.047)	17.25	0.042
Psycholeptic polypills	0.682 (0.681–0.683)	0.439 (0.438–0.440)	0.558 (0.557–0.559)	0.810 (0.809–0.811)	0.866 (0.865–0.867)	27.01	0.023
Antidementia drugs	0.069 (0.068–0.069)	0.065 (0.064–0.065)	0.065 (0.065–0.066)	0.103 (0.102–0.103)	0.122 (0.122–0.123)	77.69	0.26
Mood stabilizers	0.029 (0.028–0.029)	0.021 (0.020–0.021)	0.022 (0.022–0.023)	0.029 (0.029–0.029)	0.037 (0.036–0.037)	28.41	0.40
ADHD medications	0.016 (0.016–0.017)	0.013 (0.012–0.013)	0.007 (0.007–0.007)	0.007 (0.007–0.007)	0.008 (0.008–0.008)	−50.28	0.18
Drugs used in addictive disorders	0.004 (0.004–0.004)	0.003 (0.003–0.003)	0.007 (0.007–0.007)	0.002 (0.002–0.002)	0.001 (0.001–0.001)	−65.45	0.15

ADHD, attention deficit hyperactivity disorder.

^aThe relative increase in the prescription prevalence of psychotropic medications in 2017 compared to the prevalence in 2013 was assessed by the formula: $Relativeincrease(\%)=\frac{Prevalenc{e}_{2017}-Prevalenc{e}_{2013}}{Prevalenc{e}_{2013}}\times 100$.

^bThe P-values for the trend in prescription prevalence was from a linear regression model including year, age group (0–14, 15–64, and ≥65), and sex.